Drug intelligence / Profile preview

cannabidiol + valproic acid

Development stage: Unknown
Lead developer: Jazz Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination of two medications used for treating seizure disorders. Cannabidiol is a cannabis-derived medication that treats certain types of seizures, while valproic acid is an anticonvulsant that works in brain tissue to stop seizures. When used together, these medications require careful monitoring due to potential interactions, particularly regarding liver function and sedation effects.

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)SIGMAR1 (Sigma non-opioid intracellular receptor 1)ADORA1 (Adenosine receptor A1 subtype)CNR1 (Cannabinoid receptor 1)GABRR (GABA-A receptor subunit rho)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on cannabidiol + valproic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabidiol + valproic acid.

Explore the full profile